ocaperidone ocaperidone ocaperidone (r 79598) is a benzisoxazole antipsychotic. it was initially developed by janssen, later licensed to french laboratory neuro3d and then acquired in 2007 by german company evotec. it was found to be more potent than risperidone in animal studies, but its testing was abandoned in 2010 after unfavorable results in human phase ii trials, as while it was effective at controlling symptoms of schizophrenia, ocaperidone produced an unacceptable amount of extrapyramidal side effects. ocaperidone names preferred iupac name 3--2,9-dimethyl-4h-pyridopyrimidin-4-one identifiers cas number 129029-23-8 y 3d model (jsmol) interactive image chemspider 64451 iuphar/bps 46 kegg d02675 mesh c072259 pubchem cid 71351 unii 26hus7139v y comptox dashboard (epa) dtxsid10156042 inchi inchi=1s/c24h25fn4o2/c1-15-4-3-10-29-23(15)26-16(2)19(24(29)30)9-13-28-11-7-17(8-12-28)22-20-6-5-18(25)14-21(20)31-27-22/h3-6,10,14,17h,7-9,11-13h2,1-2h3key: zzqnejilgnnoep-uhfffaoysa-ninchi=1/c24h25fn4o2/c1-15-4-3-10-29-23(15)26-16(2)19(24(29)30)9-13-28-11-7-17(8-12-28)22-20-6-5-18(25)14-21(20)31-27-22/h3-6,10,14,17h,7-9,11-13h2,1-2h3key: zzqnejilgnnoep-uhfffaoyat smiles cc1=cc=cn2c1=nc(=c(c2=o)ccn3ccc(cc3)c4=noc5=c4c=cc(=c5)f)c properties chemical formula c24h25fn4o2 molar mass 420.488 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). infobox references synthesis synthesis according to patent (ex4): the last step requires attachment of the sidechain between 3-(2-bromoethyl)-2,9-dimethyl 4h-pyridopyrimidin-4-one, cid:18995805 (1) and 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole (2) completing the convergent synthesis of ocaperidone (3)..